Results 161 to 170 of about 594,005 (300)

Facial Palsy [PDF]

open access: yesProceedings of the Royal Society of Medicine, 1973
openaire   +3 more sources

Taste Dysfunction and Bell's Palsy: A Scoping Review

open access: yesThe Laryngoscope, EarlyView.
Taste dysfunction is a well‐recognized but inconsistently reported symptom in Bell's palsy. This scoping review found that taste dysfunction is prevalent in these patients, often precedes facial weakness, and commonly improves within 6 months. Standardized, longitudinal studies employing validated psychophysical measures are needed to clarify the ...
Sherina R. Thomas   +2 more
wiley   +1 more source

Continuous and componentized facial palsy measurement alignment and clinical interpretable model. [PDF]

open access: yesNPJ Digit Med
Guan X   +30 more
europepmc   +1 more source

Dynamic and Objective Quantification of Facial Nerve Palsy Using Smartphone‐Based 3D Facial Geometry

open access: yesThe Laryngoscope, EarlyView.
This prospective study evaluated smartphone‐captured high‐resolution 3D facial geometry in 99 patients with unilateral facial nerve palsy across 207 visits and 12 healthy volunteers. Dynamic motion features combined with machine learning accurately estimated signed continuous House–Brackmann severity and identified clinically significant palsy ...
Koki Hasebe   +9 more
wiley   +1 more source

The Hidden Burden of Hemifacial Spasm: A Systematic Review of Non‐Motor Symptoms

open access: yesMovement Disorders Clinical Practice, EarlyView.
Abstract Background Hemifacial spasm (HFS) is a chronic neurological disorder characterized by involuntary contractions of facial muscles. Traditionally regarded as a motor condition, HFS encompasses a spectrum of non‐motor symptoms that are often overlooked but significantly affect patients’ quality of life.
Miriam Carvalho Soares   +2 more
wiley   +1 more source

Real‐World Patterns of Botulinum Toxin Treatment in Hyperkinetic Movement Disorders: A 9‐Year Nationwide Analysis in France

open access: yesMovement Disorders Clinical Practice, EarlyView.
Abstract Background Hyperkinetic movement disorders, including dystonia, tremor, and myoclonus, are disabling conditions often managed with botulinum toxin type A (BoNT‐A). Real‐world evidence on treatment patterns remains limited. Objective This nationwide, population‐based study aimed to evaluate trends in BoNT‐A use in France between 2015 and 2023 ...
Marion Simonetta‐Moreau   +3 more
wiley   +1 more source

Living with the Unknown: Intolerance of Uncertainty in Parkinson's Disease

open access: yesMovement Disorders Clinical Practice, EarlyView.
Abstract Background Parkinson's disease (PD) is marked by pervasive uncertainty due to fluctuating motor and non‐motor symptoms, variable treatment response, and an unpredictable clinical course. Intolerance of uncertainty (IU), a tendency to perceive ambiguity as threatening and respond with worry, avoidance, or decisional paralysis, may be ...
Bradley McDaniels   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy